Moleculin Highlights Non-Cardiotoxic Profile of Lead Annamycin Drug

Moleculin Biotech ( (MBRX) ) has provided an announcement.

On January 13, 2026, Moleculin Biotech reported that an independent expert’s review of data from 90 subjects treated with its lead drug candidate Annamycin across five clinical trials in AML and STS found no evidence of cardiotoxicity, even though most participants received doses exceeding the U.S. FDA’s recommended lifetime exposure for conventional anthracyclines. The assessment, based on serial ECGs, echocardiography with global longitudinal strain analysis and cardiac biomarkers, reinforces Moleculin’s positioning of Annamycin as a potential non-cardiotoxic, next-generation anthracycline in a cancer treatment landscape where existing anthracyclines are widely used but linked to long-term heart damage, and it supports the company’s ongoing development programs and its argument for a significant market opportunity if the safety and efficacy profile is confirmed in further studies.

The most recent analyst rating on (MBRX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.

Spark’s Take on MBRX Stock

According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.

The score is held down primarily by weak financial performance (no revenue, heavy ongoing losses and cash burn, and recently negative equity) and bearish technicals (well below major moving averages with negative MACD). Positive corporate developments (trial progress, clinical readouts, and regained Nasdaq compliance) provide support but do not fully offset the underlying funding and execution risks.

To see Spark’s full report on MBRX stock, click here.

More about Moleculin Biotech

Moleculin Biotech, Inc. is a Phase 3 clinical-stage pharmaceutical company developing therapeutic candidates for hard-to-treat tumors and certain viral diseases. Its lead program, Annamycin (also known as naxtarubicin), is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and the cardiotoxicity associated with standard anthracyclines, and is being developed for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. The company is also advancing the MIRACLE Phase 3 trial of Annamycin in combination with cytarabine for AML, as well as additional oncology and antiviral candidates including WP1066 and WP1122.

Average Trading Volume: 313,792

Technical Sentiment Signal: Sell

Current Market Cap: $12.26M

For an in-depth examination of MBRX stock, go to TipRanks’ Overview page.